Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B.

Pin-Nan ChengI-Cher FengJyh-Jou ChenHsing-Tao KuoPei-Lun LeeMing-Lung YuYen-Cheng ChiuHung-Chih ChiuShih-Chieh ChienPei-Jer ChenChun-Jen Liu

Published in: Alimentary pharmacology & therapeutics (2023)

The switch from TDF to TAF was associated with weight gain, derangements of lipid profile, and increased insulin resistance in patients with CHB. Long-term effects on these metabolic features need further investigation.

Keyphrases

weight gain
body weight
body mass index
birth weight
antiretroviral therapy
hepatitis b virus
weight loss